Skip to main
PAYS
PAYS logo

PaySign Inc (PAYS) Stock Forecast & Price Target

PaySign Inc (PAYS) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 14%
Sell 0%
Strong Sell 14%

Bulls say

PaySign Inc. is projected to achieve a 27.5% increase in total revenue for Q2/24 compared to Q2/23, with pharmaceutical revenue significantly contributing approximately 18% to the total. The company's gross profit margins have improved by 280 basis points year-over-year, driven by the growing share of higher-margin pharma revenue, which highlighted a remarkable increase from 6% in Q1/23. Additionally, PaySign reported a substantial 135% rise in adjusted EBITDA to $1.7 million, with a notable increase in adjusted EBITDA margin of 560 basis points to 12.8%, reflecting strong operational performance and profitability growth.

Bears say

PaySign Inc. reported a decline in average revenue per plasma center, which fell from $8,041 in Q3/23 to $7,991 in Q3/24, despite a significant increase in patient affordability claim volume. The company also experienced a substantial drop in unrestricted cash, down to $7 million from $17 million at the end of 2023, primarily due to increased invoicing for patient affordability claims and related payables. Additionally, operational challenges, including center closures due to adverse weather and employment shortages, have further exacerbated the company's financial pressures.

PaySign Inc (PAYS) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 0% advise Selling, and 14% predict a Strong Sell.

This aggregate rating is based on analysts' research of PaySign Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PaySign Inc (PAYS) Forecast

Analysts have given PaySign Inc (PAYS) a Buy based on their latest research and market trends.

According to 7 analysts, PaySign Inc (PAYS) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PaySign Inc (PAYS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.